高级搜索

伊斑膦酸钠对前列腺癌骨转移患者去势治疗后骨密度的影响

张 强, 马合苏提, 白 强, 杨志刚, 霍日查

张 强, 马合苏提, 白 强, 杨志刚, 霍日查. 伊斑膦酸钠对前列腺癌骨转移患者去势治疗后骨密度的影响[J]. 肿瘤防治研究, 2014, 41(02): 131-133. DOI: 10.3971/j.issn.1000-8578.2014.02.009
引用本文: 张 强, 马合苏提, 白 强, 杨志刚, 霍日查. 伊斑膦酸钠对前列腺癌骨转移患者去势治疗后骨密度的影响[J]. 肿瘤防治研究, 2014, 41(02): 131-133. DOI: 10.3971/j.issn.1000-8578.2014.02.009
shu
ZHANG Qiang, MA Hesuti, BAI Qiang, YANG Zhigang, HUO Richa. Effects of Ibandronic Acid Sodium on Bone Mineral Density of Prostate Cancer Patients with Bone Metastasis after Androgen Deprivation Therapy[J]. Cancer Research on Prevention and Treatment, 2014, 41(02): 131-133. DOI: 10.3971/j.issn.1000-8578.2014.02.009
Citation: ZHANG Qiang, MA Hesuti, BAI Qiang, YANG Zhigang, HUO Richa. Effects of Ibandronic Acid Sodium on Bone Mineral Density of Prostate Cancer Patients with Bone Metastasis after Androgen Deprivation Therapy[J]. Cancer Research on Prevention and Treatment, 2014, 41(02): 131-133. DOI: 10.3971/j.issn.1000-8578.2014.02.009
shu

伊斑膦酸钠对前列腺癌骨转移患者去势治疗后骨密度的影响

  • 1.014040 内蒙古包头，包头市中心医院泌尿外科；2.疆维吾尔自治区人民医院泌尿男科；3.上海交通大学医学院附属新华医院泌尿外科

详细信息
    作者简介:

    张强（1982-），男，硕士，主治医师，主要从事泌尿系肿瘤研究

    通讯作者:

    白强，E-mail：baiqiang555@aliyun.com

  • 中图分类号: R737.25

Effects of Ibandronic Acid Sodium on Bone Mineral Density of Prostate Cancer Patients with Bone Metastasis after Androgen Deprivation Therapy

  • 1.Department of Urology, Baotou Central Hospital, Baotou 014040, China; 2. Department of Urology and Andrology, Xinjiang Uygur Autonomous Region People's Hospital; 3.Department of Urology, Shanghai Jiaotong University Affi liated Xinhua Hospital

摘要

    摘要
  • 摘要: 目的 评估伊斑膦酸钠对前列腺癌骨转移患者药物去势治疗后骨密度的影响。方法 晚期前列腺癌患者30例，给予最大雄激素阻断治疗，随机分为两组，治疗组15例给予伊斑膦酸钠治疗（4 mg，每月一次，静脉滴注），对照组15例未给予伊斑膦酸钠治疗。两组患者去势治疗前骨密度指标差异无统计学意义（P>0.05）；观察去势治疗后3、6和12月时的骨密度变化。结果 治疗3月时，两组患者骨密度指标均有下降，但差异无统计学意义（P>0.05）；6月时，治疗组骨密度增加，对照组骨密度下降，差异仍无统计学意义（P>0.05）；12月时，骨密度差异有统计学意义（P=0.001）。结论 前列腺癌患者接受药物去势治疗后12月时其骨密度较治疗前明显降低，而伊斑膦酸钠可减缓前列腺癌患者接受药物去势治疗后骨密度下降，减少骨丢失。

     

    Abstract: Objective To evaluate the effects of ibandronic acid sodium on bone mineral density (BMD) of prostate cancer patients with bone metastasis after androgen deprivation therapy. Methods Thirty cases of advanced prostate cancer patients were recruited in this study and received maximal androgen blockade therapy. Fifteen patients were randomized into the treatment group and received intravenous ibandronic acid sodium (4 mg, once a month, intravenous drip), and the other 15 patients were in the control group without ibandronic acid sodium treatment. There was no statistical difference in BMD index between two groups before androgen deprivation therapy. BMD of the lumber spine (L2-3) and the femoral neck were measured by dual-energy X-ray absorptiometry after 3, 6 and 12 months of treatment, respectively. Results After 3 months of treatment, BMD value was decreased in both group and there was no statistical difference(P>0.05). After 6 months, BMD was increased in the treatment group while decreased in the control group, and still with no statistical difference（P>0.05）. After 12 months, the difference in both groups was statistically different (P=0.001). Conclusion The BMD in prostate cancer patients was signifi cantly decreased after 12 months of androgen deprivation therapy, while ibandronic acid sodium could retard the decrease.

     

    • HTML全文
    • 参考文献(13)
  • [1] Schroder FH. Hormonal therapy of prostate cancer [M] // W.B. Saunders. 9th ed. Walsh Campbell’s Urology. The United States: W.B. Saunders, 2007:3280.
    [2] Body JJ. Prevention and treatment of side-effects of systemic treatment: bone loss[J]. Ann Oncol,2010,21 Suppl 7:vii 180-5.
    [3] Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives[J]. Oncologist,2008,13(2):187-95.
    [4] Meier C, Nguyen TV, Handelsman DJ, et al. Endogenous sex hormones and incident fracture risk in older men: the dubbo osteoporosis epidemiology study[J]. Arch Intern Med,2008,168(1):47-54.
    [5] Serpa Neto A, Tobias-Machado M, Esteves MA, et al. A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma[J]. BMC Urol,2010,10:9.
    [6] Yang LP, Deng JH, Wang LS, et al. Influence of castration in the treatment of prostate cancinoma on bone mineral density[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi,2007,14(6):461-2.[杨柳平, 邓军洪,王良圣,等.去势治疗对前列腺癌患者骨密度的影响[J]. 中华肿瘤防治杂志,2007,14(6):461-2.]
    [7] Wang W, Yuasa T, Tsuchiya N, et al. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy[J]. Endocr Relat Cancer,2008,15(4):943-52.
    [8] Lattouf JB, Saad F. Bone health in nonmetastatic prostate cancer: what’s the big deal?[J]. Curr Oncol,2010,17 Suppl 2:S49-54.
    [9] Coleman RE. Risks and benefi ts of bisphosphonates[J].Br J Cancer, 20 08,98(11):1736-40.
    [10] Liu YJ, Lu JY. Systematic review of the study on Bisphosphonates for the treatment of advanced prostate cancer[J]. Zhongguo Nan Ke Xue Za Zhi,2009,23(8):33-7,44. [刘永江, 陆敬义.二 磷酸盐治疗前列腺癌骨转移的系统评价[J].中国男科学杂志 20 09,23(8):33-7,44.]
    [11] Montague R, Hart CA, George NJ, et al. Differential inhibition of invasion and proliferation by bisphosphonates: antimetastatic potential of Zoledronic acid in prostate cancer[J]. Eur Urol,2004,46(3):389-401.
    [12] Greenspan SL, Nelson JB, Trump DL, et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy[J]. J Clin Oncol,2008,26(27):4426-34.
    [13] Satoh T, Kimura M, Matsumoto K, et al. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naïve prostate carcinoma[J]. Cancer,2009,115(15):3468-74.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1325
  • HTML全文浏览量:  311
  • PDF下载量:  622
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-09-01
  • 修回日期:  2013-10-15
  • 刊出日期:  2014-02-24

目录

摘要
HTML全文
    参考文献(13)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：11973589 今日访问：9892

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭